Envoy Medical to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025
White Bear Lake, Minnesota--(Newsfile Corp. - September 8, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced today announced that Brent Lucas, Envoy Medical's Chief Executive Officer, will present virtually at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025 in New York City. Mr. Lucas' presentation is now av
Biotechnology, Healthcare and Hospitals
2025-09-08 8:00 AM EDT | Envoy Medical, Inc.
Optimi Announces Public Filing of Registration Statement for Proposed U.S. Initial Public Offering
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company") a Canadian drug manufacturer of MDMA and naturally-derived psilocybin announces that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of its common shares in the United States. The number of common share
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-08 7:00 AM EDT | Optimi Health Corp.
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news release dated August 5, 2025, it has closed an initial tranche (the "Initial Tranche") of its previously announced $1,000,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 16,162,500 unit
Biotechnology, Pharmaceuticals, Health
2025-09-05 4:58 PM EDT | PreveCeutical Medical Inc.
InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that the Company will be participating in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025, in New York. During the conference, members of InMe
Biotechnology, Pharmaceuticals
2025-09-05 1:33 PM EDT | InMed Pharmaceuticals
Genix Pharmaceuticals Closes Private Placement
Vancouver, British Columbia--(Newsfile Corp. - September 4, 2025) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") announces that it has closed its previously announced non-brokered private placement raising gross proceeds of $100,000. The Company has issued 2,000,000 units (each a "Unit") at a price of $0.10 per Unit. Each Unit consists of one common share of the Company (a "Share") and one transferable common share purchase warrant (a "Warra
Biotechnology, Pharmaceuticals, Health
2025-09-04 4:15 PM EDT | Genix Pharmaceuticals Corp.
iSpecimen Approached by Crypto Currency Companies for $200 Million Treasury Discussions
Woburn, Massachusetts--(Newsfile Corp. - September 4, 2025) - iSpecimen Inc. (NASDAQ: ISPC), (the "Company"), a technology-enabled company modernizing the way human biospecimens are sourced for scientific research, today announced an update on its major strategic initiative aimed at integrating digital assets into its business model. The Company had previously announced that it is pursuing a strategic initiative aimed at integrating digital assets into its business model, by seeking to build
2025-09-04 4:05 PM EDT | iSpecimen Inc.
Optimind Pharma Announces Termination of Letter of Intent
Toronto, Ontario--(Newsfile Corp. - September 4, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces that its previously announced non-binding letter of intent dated March 18, 2025 with Monjin Interviews Private Limited ("Monjin"), with respect to the Company's acquisition of Monjin, has been mutually terminated by the parties. The Company is continuing to evaluate and review alternative acquisition opportunities. About the
Biotechnology, Cannabis, Health, Psychedelics
2025-09-04 4:00 PM EDT | Optimind Pharma Corp.
PreveCeutical Announces Arrangement Agreement with BioGene Therapeutics
Vancouver, British Columbia--(Newsfile Corp. - September 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (the "Company" or "PreveCeutical") announces that it has entered into a definitive arrangement agreement (the "Arrangement Agreement") dated September 3, 2025 with its subsidiary, BioGene Therapeutics Inc. ("BioGene"), pursuant to which PreveCeutical intends to spin-out 12,000,000 common shares of BioGene (the "BioGene Spinout
Biotechnology, Pharmaceuticals, Health
2025-09-04 4:00 PM EDT | PreveCeutical Medical Inc.
Hemostemix's VesCell.Health Launched in Florida
Calgary, Alberta--(Newsfile Corp. - September 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, today announces it la
Biotechnology, Pharmaceuticals, Health
2025-09-04 9:47 AM EDT | Hemostemix Inc.
Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
Encinitas, California--(Newsfile Corp. - September 4, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its Chief Financial Officer, Melissa Tosca, CPA, will showcase the Company's pipeline of therapies targeting inherited and inflammatory retinal diseases at the H.C. Wainwright 27th Annual Global Investment Conference. Presentation Details
Biotechnology, Pharmaceuticals
2025-09-04 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Howie's 17+ Years After VesCell(TM): Following Hemostemix's Heart Patients
Calgary, Alberta--(Newsfile Corp. - September 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, celebrated the 17+ ye
Biotechnology, Pharmaceuticals, Health
2025-09-03 8:47 AM EDT | Hemostemix Inc.
Envoy Medical Successfully Reaches Three-Month Follow-Up Milestone in Clinical Trial of the Acclaim Fully Implanted Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - September 3, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted technologies, today announced that the patients in the first stage of its pivotal clinical trial for the investigational Acclaim® fully implanted cochlear implant have successfully reached their three-month follow-up milestone. During this timeframe, no serious adverse events (SAEs) or unan
Biotechnology, Healthcare and Hospitals
2025-09-03 8:00 AM EDT | Envoy Medical, Inc.
Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio today announced th
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-09-03 7:45 AM EDT | Phio Pharmaceuticals Corp.
OS Therapies to Participate in Upcoming Investor Conferences in September 2025
New York, New York--(Newsfile Corp. - September 3, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will participate in the upcoming investor conferences: Cantor Global Healthcare Conference 2025 being held September 3-5, 2025 in New York City. Management will be available for meetings with instituti
2025-09-03 7:40 AM EDT | OS Therapies
Optimi Health Announces Launch of Psilocybin Capsules in Australia for Treatment-Resistant Depression
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of GMP psychedelic medicines, is pleased to announce the commercial launch of its natural psilocybin capsules in Australia, which are now being prescribed to patients with Treatment-Resistant Depression ("TRD") under the Authorised Prescriber Scheme. The initial shipment of 1,000 psilocybin capsules, each conta
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-03 7:30 AM EDT | Optimi Health Corp.
Scryb Reports Financial Results for Q3 2025: Positive Outlook for Cybeats Technologies Corp.
Toronto, Ontario--(Newsfile Corp. - September 3, 2025) - Scryb Inc. (CSE: SCYB) ("Scryb'' or the "Company") has filed financial results for its third quarter ended June 30, 2025 ("Q3 2025"), and also provides commentary on Scryb's largest holding, Cybeats, which filed its second quarter ended June 30, 2025 Interim Financial Statements and Management's Discussion and Analysis ("MD&A"). Scryb's reported results for Q3 2025 reflect the transition to equity accounting for C
Biotechnology, Healthcare and Hospitals, Health
2025-09-03 7:20 AM EDT | Scryb Inc.
TempraMed Closes Oversubscribed C$7.4M Financing and Advances Toward Go Public Listing
Sammamish, Washington--(Newsfile Corp. - September 3, 2025) - TempraMed Ltd. ("TempraMed" or the "Company"), a medical technology innovator redefining how temperature-sensitive medications are stored, managed and protected, is pleased to announce significant corporate and capital markets milestones, including the successful close of an oversubscribed C$7.4 million private placement financing and strong progress toward its public listing on the Canadian Securities Exchange (CSE), expected mid-
Technology, Biotechnology, Pharmaceuticals, Health
2025-09-03 7:00 AM EDT | TempraMed Technologies Ltd
CellCentric Announces First Patients Dosed with Inobrodib in Combination with Bispecific Antibodies in Multiple Myeloma
United Kingdom and Boston, Massachusetts--(Newsfile Corp. - September 3, 2025) - CellCentric, a clinical-stage biotechnology company developing inobrodib, a first-in-class, oral p300/CBP inhibitor for the treatment of mul
2025-09-03 7:00 AM EDT | CellCentric, Inc
BioHarvest Sciences to Host a Virtual Investor Webinar on September 10, 2025 at 1:00 PM ET
Rehovot, Israel--(Newsfile Corp. - September 2, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management will host a Virtual Investor Webinar on Wednesday, September 10, 2025 at 1:00 p.m. Eastern time. CEO Ilan Sobel will host the virtual investor webinar to provide a corporate update
Biotechnology, Pharmaceuticals, Health
2025-09-02 8:30 AM EDT | BioHarvest Sciences Inc.
OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting
New York, New York--(Newsfile Corp. - September 2, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today provided stakeholders with a detailed
2025-09-02 7:40 AM EDT | OS Therapies